Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Induced pluripotent stem cells in cardiovascular drug discovery.

Mercola M, Colas A, Willems E.

Circ Res. 2013 Feb 1;112(3):534-48. doi: 10.1161/CIRCRESAHA.111.250266. Review.

2.

A review of human pluripotent stem cell-derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication standards.

Mordwinkin NM, Burridge PW, Wu JC.

J Cardiovasc Transl Res. 2013 Feb;6(1):22-30. doi: 10.1007/s12265-012-9423-2. Epub 2012 Nov 15. Review.

3.

The future of induced pluripotent stem cells for cardiac therapy and drug development.

Thorrez L, Sampaolesi M.

Curr Pharm Des. 2011 Oct;17(30):3258-70. Review.

PMID:
21919876
4.

Novel stem cell-based drug discovery platforms for cardiovascular disease.

Adams WJ, García-Cardeña G.

J Biomol Screen. 2012 Oct;17(9):1117-27. Epub 2012 Aug 1. Review.

PMID:
22853930
5.

Structural and functional screening in human induced-pluripotent stem cell-derived cardiomyocytes accurately identifies cardiotoxicity of multiple drug types.

Doherty KR, Talbert DR, Trusk PB, Moran DM, Shell SA, Bacus S.

Toxicol Appl Pharmacol. 2015 May 15;285(1):51-60. doi: 10.1016/j.taap.2015.03.008. Epub 2015 Apr 2.

PMID:
25841593
6.

Cardiac safety pharmacology: from human ether-a-gogo related gene channel block towards induced pluripotent stem cell based disease models.

Kraushaar U, Meyer T, Hess D, Gepstein L, Mummery CL, Braam SR, Guenther E.

Expert Opin Drug Saf. 2012 Mar;11(2):285-98. doi: 10.1517/14740338.2012.639358. Epub 2011 Nov 22. Review.

PMID:
22103746
7.

Human Induced Pluripotent Stem Cell-Derived Cardiac Progenitor Cells in Phenotypic Screening: A Transforming Growth Factor-β Type 1 Receptor Kinase Inhibitor Induces Efficient Cardiac Differentiation.

Drowley L, Koonce C, Peel S, Jonebring A, Plowright AT, Kattman SJ, Andersson H, Anson B, Swanson BJ, Wang QD, Brolen G.

Stem Cells Transl Med. 2016 Feb;5(2):164-74. doi: 10.5966/sctm.2015-0114. Epub 2015 Dec 18.

PMID:
26683871
8.

Disease characterization using LQTS-specific induced pluripotent stem cells.

Egashira T, Yuasa S, Suzuki T, Aizawa Y, Yamakawa H, Matsuhashi T, Ohno Y, Tohyama S, Okata S, Seki T, Kuroda Y, Yae K, Hashimoto H, Tanaka T, Hattori F, Sato T, Miyoshi S, Takatsuki S, Murata M, Kurokawa J, Furukawa T, Makita N, Aiba T, Shimizu W, Horie M, Kamiya K, Kodama I, Ogawa S, Fukuda K.

Cardiovasc Res. 2012 Sep 1;95(4):419-29. doi: 10.1093/cvr/cvs206. Epub 2012 Jun 27.

9.

Human-induced pluripotent stem cell models of inherited cardiomyopathies.

Karakikes I, Termglinchan V, Wu JC.

Curr Opin Cardiol. 2014 May;29(3):214-9. doi: 10.1097/HCO.0000000000000049. Review.

10.

Impacts of recent advances in cardiovascular regenerative medicine on clinical therapies and drug discovery.

Murata M, Tohyama S, Fukuda K.

Pharmacol Ther. 2010 May;126(2):109-18. doi: 10.1016/j.pharmthera.2010.01.010. Epub 2010 Feb 13. Review.

PMID:
20156482
11.

Human induced pluripotent stem cells and their use in drug discovery for toxicity testing.

Scott CW, Peters MF, Dragan YP.

Toxicol Lett. 2013 May 10;219(1):49-58. doi: 10.1016/j.toxlet.2013.02.020. Epub 2013 Mar 5. Review.

PMID:
23470867
12.

Induced pluripotent stem cells for regenerative cardiovascular therapies and biomedical discovery.

Nsair A, MacLellan WR.

Adv Drug Deliv Rev. 2011 Apr 30;63(4-5):324-30. doi: 10.1016/j.addr.2011.01.013. Epub 2011 Mar 1. Review.

13.

Induced pluripotent stem cell-derived cardiomyocytes for drug development and toxicity testing.

Sinnecker D, Laugwitz KL, Moretti A.

Pharmacol Ther. 2014 Aug;143(2):246-52. doi: 10.1016/j.pharmthera.2014.03.004. Epub 2014 Mar 19. Review.

14.

The application of phenotypic high-throughput screening techniques to cardiovascular research.

Etzion Y, Muslin AJ.

Trends Cardiovasc Med. 2009 Aug;19(6):207-12. doi: 10.1016/j.tcm.2009.12.006. Review.

15.

Induced pluripotent stem cells: opportunities as research and development tools in 21st century drug discovery.

Rowntree RK, McNeish JD.

Regen Med. 2010 Jul;5(4):557-68. doi: 10.2217/rme.10.36.

PMID:
20632859
16.

In vitro uses of human pluripotent stem cell-derived cardiomyocytes.

Matsa E, Denning C.

J Cardiovasc Transl Res. 2012 Oct;5(5):581-92. Epub 2012 May 26. Review.

PMID:
22639342
17.

Stem cells for drug screening.

Laposa RR.

J Cardiovasc Pharmacol. 2011 Sep;58(3):240-5. doi: 10.1097/FJC.0b013e31821823f5.

PMID:
21499120
18.

Induced pluripotent stem cells--opportunities for disease modelling and drug discovery.

Grskovic M, Javaherian A, Strulovici B, Daley GQ.

Nat Rev Drug Discov. 2011 Nov 11;10(12):915-29. doi: 10.1038/nrd3577. Review.

PMID:
22076509
19.

Induced pluripotent stem cells: the new patient?

Bellin M, Marchetto MC, Gage FH, Mummery CL.

Nat Rev Mol Cell Biol. 2012 Nov;13(11):713-26. doi: 10.1038/nrm3448. Epub 2012 Oct 4. Review.

PMID:
23034453
20.

Phenotypic screening with human iPS cell-derived cardiomyocytes: HTS-compatible assays for interrogating cardiac hypertrophy.

Carlson C, Koonce C, Aoyama N, Einhorn S, Fiene S, Thompson A, Swanson B, Anson B, Kattman S.

J Biomol Screen. 2013 Dec;18(10):1203-11. doi: 10.1177/1087057113500812. Epub 2013 Sep 26.

PMID:
24071917
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk